Literature DB >> 7879422

Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines.

J B Ulmer1, R R Deck, C M DeWitt, A Friedman, J J Donnelly, M A Liu.   

Abstract

Dose-response relationships were investigated between dose of influenza virus haemagglutinin (HA) or nucleoprotein (NP) DNA vaccines, and immunogenicity and protective efficacy based on humoral and cellular immunity. In mice, intramuscular (i.m.) injection of HA or NP DNA, at doses of 100 ng to 1 microgram, was found to generate haemagglutination inhibiting (HI) antibodies and cytotoxic T-lymphocytes, respectively, and provide protection in influenza virus challenge models. A direct correlation between the amount of DNA injected and the level of HI antibody was observed. In non-human primates, high-titre neutralizing antibodies were induced in animals vaccinated with as little as 10 micrograms of HA DNA. These results indicate that low doses of DNA administered by i.m. injection provide protective efficacy against influenza.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7879422     DOI: 10.1016/0264-410x(94)90081-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

Review 1.  Plasmid DNA vaccines. Immunology, tolerance, and autoimmunity.

Authors:  G Mor; M Eliza
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

Review 2.  Update on prostate cancer vaccines.

Authors:  Charles G Drake
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

3.  Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations.

Authors:  S W Lee; Y C Sung
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

4.  Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes.

Authors:  J Hinkula; C Svanholm; S Schwartz; P Lundholm; M Brytting; G Engström; R Benthin; H Glaser; G Sutter; B Kohleisen; V Erfle; K Okuda; H Wigzell; B Wahren
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 5.  The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.

Authors:  A Sally Davis; Jeffery K Taubenberger; Mike Bray
Journal:  Antiviral Res       Date:  2015-03-05       Impact factor: 5.970

Review 6.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

7.  Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1.

Authors:  A Ihata; S Watabe; S Sasaki; A Shirai; J Fukushima; K Hamajima; J Inoue; K Okuda
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

8.  Therapy of experimental influenza virus infection with pyrrolidine dithiocarbamate.

Authors:  Nadine Wiesener; Christin Zimmer; Nadine Jarasch-Althof; Peter Wutzler; Andreas Henke
Journal:  Med Microbiol Immunol       Date:  2010-12-21       Impact factor: 3.402

9.  Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus.

Authors:  Ke Xu; Zhi-Yang Ling; Liang Sun; Ying Xu; Chao Bian; Yuan He; Wei Lu; Ze Chen; Bing Sun
Journal:  Viral Immunol       Date:  2011-02       Impact factor: 2.257

10.  Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus.

Authors:  R J Phillpotts; K Venugopal; T Brooks
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.